MYC and neoplasm: Two phase II studies, in particular, proved the effectiveness of combining the ATR inhibitor berzosertib with chemotherapeutics to treat platinum‐resistant high‐grade serous ovarian cancer and lung small cell neuroendocrine cancers [208, 209], two aggressive forms of neoplasia bearing frequent amplification of MYC family members [210, 211, 212].